BFC Planning’s Definium Therapeutics DFTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$765K Sell
19,087
-6,837
-26% -$288K 0.03% 468
2026
Q2
$1.22M Buy
25,924
+112
+0.4% +$2.77K 0.05% 349
2026
Q1
$488K Sell
25,812
-500
-2% -$8.48K 0.02% 575
2025
Q4
$352K Buy
26,312
+26,261
+51,492% +$325K 0.02% 661
2025
Q3
$601 Buy
+51
New +$476 ﹤0.01% 2723
2025
Q2
– Sell
-51
Closed -$298 – 2776
2025
Q1
$298 Hold
51
– – ﹤0.01% 2556
2024
Q4
$355 Hold
51
– – ﹤0.01% 2499
2024
Q3
$290 Buy
+51
New +$355 ﹤0.01% 2503

Other funds holding DFTX

BFC Planning's DFTX Position: Q3 2026 in Review

BFC Planning reduced its Definium Therapeutics (DFTX) stake by 26% in Q3 2026, selling an estimated $288K and leaving 19,087 shares worth $765K. The position accounts for 0.03% of the portfolio, ranked #468.

BFC Planning first reported a position in DFTX in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.22M in Q2 2026. 253 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

  • BFC Planning held 19,087 shares of Definium Therapeutics worth $765K as of Q3 2026.
  • BFC Planning sold 6,837 Definium Therapeutics shares in Q3 2026, an estimated $288K.
  • Definium Therapeutics made up 0.03% of BFC Planning's portfolio in Q3 2026, its #468 holding.
  • BFC Planning first reported a position in Definium Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • BFC Planning's Definium Therapeutics position peaked at $1.22M in Q2 2026.
  • 253 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.